COORDINATED METABOLIC REPROGRAMMING IN RESPONSE TO PRODUCTIVE VIRAL INFECTIONS

• US 20170304293A1
• Filed: 10/16/2015
• Published: 10/26/2017
• Est. Priority Date: 10/24/2014
• Status: Active Grant

• Current Assignee: St Jude Children's Research Hospital Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: St Jude Children's Research Hospital Incorporated (Abbott Laboratories Incorporated)
• Inventors: Smallwood, Heather S., Morfouace, Marie, Roussel, Martine F., Thomas, Paul G.
• Granted Patent: US 11,083,725 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/277 having a ring, e.g. verapamil
• CPC Class Codes: A61K 31/34 having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
• CPC Class Codes: A61K 31/352 condensed with carbocyclic rings, e.g. methantheline cannabinoids A61K31/658
• CPC Class Codes: A61K 31/365 Lactones
• CPC Class Codes: A61K 31/415 1,2-Diazoles
• CPC Class Codes: A61K 31/416 condensed with carbocyclic ring systems, e.g. indazole
• CPC Class Codes: A61K 31/4164 1,3-Diazoles
• CPC Class Codes: A61K 31/4174 Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
• CPC Class Codes: A61K 31/427 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 31/433 Thidiazoles
• CPC Class Codes: A61K 31/4439 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole nicotine A61K31/465
• CPC Class Codes: A61K 31/454 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• CPC Class Codes: A61K 31/4745 condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48
• CPC Class Codes: A61K 31/505 Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 31/555 containing heavy metals, e.g. hemin, hematin, melarsoprol
• CPC Class Codes: A61K 31/7004 Monosaccharides having only carbon, hydrogen and oxygen atoms
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 31/12 Antivirals

Abstract

The invention generally relates to methods of treating viral infections using known drugs and pharmaceutical compositions comprising same. More specifically, the disclosed methods are useful for the treatment of viral infections that are enveloped viruses. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Claims

1. A method for treating viral infection, the method comprising the step of administering to the subject an effective amount of at least one compound having a structure selected from:

2. The method of claim 1, wherein the viral infection is selected from human immunodeficiency virus (HIV), human papillomavirus (HPV), influenza, chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, and viral pneumonia.

3. The method of claim 2, wherein the viral infection is influenza.

4. The method of claim 1, wherein the viral infection is an enveloped virus.

5. The method of claim 4, wherein the enveloped virus is a respiratory virus.

6. The method of claim 1, wherein the subject is a mammal.

7. The method of claim 6, wherein the mammal is a human.

8. The method of claim 1, wherein the subject has been diagnosed with a need for treatment of the viral infection prior to the administering step.

9. The method of claim 1, further comprising the step of identifying a subject in need of treatment of the viral infection.

10. The method of claim 1, wherein the effective amount is a therapeutically effective amount.

11. The method of claim 1, wherein the effective amount is a prophylactically effective amount.

12. The method off claim 1, wherein the compound has the structure:

13. A pharmaceutical composition comprising an effective amount of at least one compound having a structure selected from:

14. The composition of claim 13, wherein the effective amount is a therapeutically effective amount.

15. The composition of claim 13, wherein the effective amount is a prophylactically effective amount.

16. The composition of claim 13, wherein the compound has the structure:

17. A kit comprising an effective amount of at least one compound having a structure selected from:

18. The kit of claim 17, wherein the at least one compound and the at least one agent are co-packaged.

19. The kit of claim 17, wherein the at least one compound and the at least one agent are co-formulated.

20. The kit of claim 17, wherein the at least one compound has the structure: